Compare AGPU & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGPU | RDHL |
|---|---|---|
| Founded | 2002 | 2009 |
| Country | United States | Israel |
| Employees | 24 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 5.6M |
| IPO Year | N/A | 2012 |
| Metric | AGPU | RDHL |
|---|---|---|
| Price | $1.88 | $0.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 67.7K | 34.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $486.27 | $381.91 |
| Revenue Next Year | $65.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $0.91 |
| 52 Week High | $9.00 | $3.60 |
| Indicator | AGPU | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 31.98 | 37.34 |
| Support Level | N/A | $0.91 |
| Resistance Level | $2.51 | $1.45 |
| Average True Range (ATR) | 0.32 | 0.07 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 1.66 | 10.45 |
Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, it aims to provide access to bare-metal GPUs at scale for both emerging and established organizations. It plans to monetize access to the network by serving enterprise customers that require guaranteed capacity, service-level agreements, and a counterparty operating within conventional corporate and regulatory frameworks.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.